Information Provided By: 
Fly News Breaks for February 9, 2018
HOLX
Feb 9, 2018 | 07:45 EDT
Cowen analyst Doug Schenkel said Q2 results from Hologic were fine and with 2018 guidance reiterated, his Outperform thesis remains intact. The analyst said the pillars to his thesis remain, including the core business sustaining is mid-single digit growth, Cynosure stabilizing and tax reform boosting free cash flow. Schenkel reiterated his Outperform rating and $51 price target on Hologic shares.
News For HOLX From the Last 2 Days
There are no results for your query HOLX
